» Articles » PMID: 36692401

Multicenter Validation of Abbreviated MRI for Detecting Early-Stage Hepatocellular Carcinoma

Abstract

Background Abbreviated MRI is a proposed paradigm shift for hepatocellular carcinoma (HCC) surveillance, but data on its performance are lacking for histopathologically confirmed early-stage HCC. Purpose To evaluate the sensitivity and specificity of dynamic contrast-enhanced abbreviated MRI for early-stage HCC detection, using surgical pathologic findings as the reference standard. Materials and Methods This retrospective study was conducted at three U.S. liver transplant centers in patients with cirrhosis who underwent liver resection or transplant between January 2009 and December 2019 and standard "full" liver MRI with and without contrast enhancement within 3 months before surgery. Patients who had HCC-directed treatment before surgery were excluded. Dynamic abbreviated MRI examinations were simulated from the presurgical full MRI by selecting the coronal T2-weighted and axial three-dimensional fat-suppressed T1-weighted dynamic contrast-enhanced sequences at precontrast, late arterial, portal venous, and delayed phases. Two abdominal radiologists at each center independently interpreted the simulated abbreviated examinations with use of the Liver Imaging Reporting and Data System version 2018. Patients with any high-risk liver observations (>LR-3) were classified as positive; otherwise, they were classified as negative. With liver pathologic findings as the reference standard for the presence versus absence of early-stage HCC, the sensitivity, specificity, and their 95% CIs were calculated. Logistic regression was used to identify factors associated with correct classification. Results A total of 161 patients with early-stage HCC (median age, 62 years [IQR, 58-67 years]; 123 men) and 138 patients without HCC (median age, 55 years [IQR, 47-63 years]; 85 men) were confirmed with surgical pathologic findings. The sensitivity and specificity of abbreviated MRI were 88.2% (142 of 161 patients) (95% CI: 83.5, 92.5) and 89.1% (123 of 138 patients) (95% CI: 84.4, 93.8), respectively. Sensitivity was lower for Child-Pugh class B or C versus Child-Pugh class A cirrhosis (64.1% vs 94.2%; < .001). Conclusion With surgical pathologic findings as the reference standard, dynamic abbreviated MRI had high sensitivity and specificity for early-stage hepatocellular carcinoma detection in patients with compensated cirrhosis but lower sensitivity in those with decompensated cirrhosis. © RSNA, 2023 See also the editorial by Kim in this issue.

Citing Articles

Cost-effectiveness of an outreach program for HCC screening in patients with cirrhosis: a microsimulation modeling study.

Gurley T, Hernaez R, Cerda V, Thomas T, Narasimman M, Mittal S EClinicalMedicine. 2025; 81:103113.

PMID: 40040860 PMC: 11876903. DOI: 10.1016/j.eclinm.2025.103113.


Comparative evaluation of non-contrast MRI versus gadoxetic acid-enhanced abbreviated protocols in detecting colorectal liver metastases.

Dai H, Yan C, Jia X, Xiao Y, Liang X, Yang C Insights Imaging. 2025; 16(1):3.

PMID: 39747788 PMC: 11695540. DOI: 10.1186/s13244-024-01886-3.


Gadoxetic acid disodium (Gd-EOB-DTPA) contrast-enhanced abbreviated magnetic resonance imaging (MRI) for hepatocellular carcinoma surveillance in at-risk patients: a multi-center study in China.

He X, Li Y, Han D, Zhou Y, Zhang J, Xu Q Quant Imaging Med Surg. 2024; 14(12):8520-8537.

PMID: 39698720 PMC: 11651963. DOI: 10.21037/qims-24-941.


Exam quality of ultrasound and dynamic contrast-enhanced abbreviated MRI and impact on early-stage HCC detection.

Seif El Dahan K, Yokoo T, Mendiratta-Lala M, Fetzer D, Davenport M, Daher D Abdom Radiol (NY). 2024; .

PMID: 39542949 DOI: 10.1007/s00261-024-04674-1.


Evolving Global Etiology of Hepatocellular Carcinoma (HCC): Insights and Trends for 2024.

Koshy A J Clin Exp Hepatol. 2024; 15(1):102406.

PMID: 39346785 PMC: 11426038. DOI: 10.1016/j.jceh.2024.102406.


References
1.
van der Pol C, Lim C, Sirlin C, McGrath T, Salameh J, Bashir M . Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy-A Systematic Review. Gastroenterology. 2018; 156(4):976-986. DOI: 10.1053/j.gastro.2018.11.020. View

2.
Henrique Lima P, Fan B, Berube J, Cerny M, Olivie D, Giard J . Cost-Utility Analysis of Imaging for Surveillance and Diagnosis of Hepatocellular Carcinoma. AJR Am J Roentgenol. 2019; 213(1):17-25. DOI: 10.2214/AJR.18.20341. View

3.
Rahib L, Wehner M, Matrisian L, Nead K . Estimated Projection of US Cancer Incidence and Death to 2040. JAMA Netw Open. 2021; 4(4):e214708. PMC: 8027914. DOI: 10.1001/jamanetworkopen.2021.4708. View

4.
Arvind A, Joshi S, Zaki T, Burkholder D, Parikh N, Singal A . Risk of Hepatocellular Carcinoma in Patients With Indeterminate (LI-RADS 3) Liver Observations. Clin Gastroenterol Hepatol. 2021; 21(4):1091-1093.e3. PMC: 9184301. DOI: 10.1016/j.cgh.2021.11.042. View

5.
Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D . Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol. 2006; 101(3):513-23. DOI: 10.1111/j.1572-0241.2006.00467.x. View